@phdthesis{Schlosser2011,
  author    = {Schlosser, Daniel},
  title     = {Quality of Experience Management in Virtual Future Networks},
  doi       = {10.25972/OPUS-5719},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-69986},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Aktuell beobachten wir eine drastische Vervielf{\"a}ltigung der Dienste und Anwendungen, die das Internet f{\"u}r den Datentransport nutzen. Dabei unterscheiden sich die Anforderungen dieser Dienste an das Netzwerk deutlich. Das Netzwerkmanagement wird durch diese Diversit{\"a}t der nutzenden Dienste aber deutlich erschwert, da es einem Datentransportdienstleister kaum m{\"o}glich ist, die unterschiedlichen Verbindungen zu unterscheiden, ohne den Inhalt der transportierten Daten zu analysieren. Netzwerkvirtualisierung ist eine vielversprechende L{\"o}sung f{\"u}r dieses Problem, da sie es erm{\"o}glicht f{\"u}r verschiedene Dienste unterschiedliche virtuelle Netze auf dem gleichen physikalischen Substrat zu betreiben. Diese Diensttrennung erm{\"o}glicht es, jedes einzelne Netz anwendungsspezifisch zu steuern. Ziel einer solchen Netzsteuerung ist es, sowohl die vom Nutzer erfahrene Dienstg{\"u}te als auch die Kosteneffizienz des Datentransports zu optimieren. Dar{\"u}ber hinaus wird es mit Netzwerkvirtualisierung m{\"o}glich das physikalische Netz so weit zu abstrahieren, dass die aktuell fest verzahnten Rollen von Netzwerkbesitzer und Netzwerkbetreiber entkoppelt werden k{\"o}nnen. Dar{\"u}ber hinaus stellt Netzwerkvirtualisierung sicher, dass unterschiedliche Datennetze, die gleichzeitig auf dem gleichen physikalischen Netz betrieben werden, sich gegenseitig weder beeinflussen noch st{\"o}ren k{\"o}nnen. Diese Arbeit  besch{\"a}ftigt sich mit ausgew{\"a}hlten Aspekten dieses Themenkomplexes und fokussiert sich darauf, ein virtuelles Netzwerk mit bestm{\"o}glicher Dienstqualit{\"a}t f{\"u}r den Nutzer zu betreiben und zu steuern. Daf{\"u}r wird ein Top-down-Ansatz gew{\"a}hlt, der von den Anwendungsf{\"a}llen, einer m{\"o}glichen Netzwerkvirtualisierungs-Architektur und aktuellen M{\"o}glichkeiten der Hardwarevirtualisierung ausgeht. Im Weiteren fokussiert sich die Arbeit dann in Richtung Bestimmung und Optimierung der vom Nutzer erfahrenen Dienstqualit{\"a}t (QoE) auf Applikationsschicht und diskutiert M{\"o}glichkeiten zur Messung und {\"U}berwachung von wesentlichen Netzparametern in virtualisierten Netzen.},
  subject      = {Netzwerkmanagement},
  language  = {en}
}
@inproceedings{SchlosserJarschelDuellietal.2010,
  author    = {Schlosser, Daniel and Jarschel, Michael and Duelli, Michael and Hoßfeld, Tobias and Hoffmann, Klaus and Hoffmann, Marco and Morper, Hans Jochen and Jurca, Dan and Khan, Ashiq},
  title     = {A Use Case Driven Approach to Network Virtualization},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-55611},
  year      = {2010},
  abstract  = {In today's Internet, services are very different in their requirements on the underlying transport network. In the future, this diversity will increase and it will be more difficult to accommodate all services in a single network. A possible approach to cope with this diversity within future networks is the introduction of support for running isolated networks for different services on top of a single shared physical substrate. This would also enable easy network management and ensure an economically sound operation. End-customers will readily adopt this approach as it enables new and innovative services without being expensive. In order to arrive at a concept that enables this kind of network, it needs to be designed around and constantly checked against realistic use cases. In this contribution, we present three use cases for future networks. We describe functional blocks of a virtual network architecture, which are necessary to support these use cases within the network. Furthermore, we discuss the interfaces needed between the functional blocks and consider standardization issues that arise in order to achieve a global consistent control and management structure of virtual networks.},
  subject      = {Virtualisierung},
  language  = {en}
}
@article{JarickBertscheStahletal.2018,
  author    = {Jarick, Marcel and Bertsche, Ute and Stahl, Mark and Schultz, Daniel and Methling, Karen and Lalk, Michael and Stigloher, Christian and Steger, Mirco and Schlosser, Andreas and Ohlsen, Knut},
  title     = {The serine/threonine kinase Stk and the phosphatase Stp regulate cell wall synthesis in Staphylococcus aureus},
  series = {Scientific Reports},
  volume    = {8},
  journal   = {Scientific Reports},
  number    = {13693},
  doi       = {10.1038/s41598-018-32109-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-177333},
  year      = {2018},
  abstract  = {The cell wall synthesis pathway producing peptidoglycan is a highly coordinated and tightly regulated process. Although the major components of bacterial cell walls have been known for decades, the complex regulatory network controlling peptidoglycan synthesis and many details of the cell division machinery are not well understood. The eukaryotic-like serine/threonine kinase Stk and the cognate phosphatase Stp play an important role in cell wall biosynthesis and drug resistance in S. aureus. We show that stp deletion has a pronounced impact on cell wall synthesis. Deletion of stp leads to a thicker cell wall and decreases susceptibility to lysostaphin. Stationary phase Δstp cells accumulate peptidoglycan precursors and incorporate higher amounts of incomplete muropeptides with non-glycine, monoglycine and monoalanine interpeptide bridges into the cell wall. In line with this cell wall phenotype, we demonstrate that the lipid II:glycine glycyltransferase FemX can be phosphorylated by the Ser/Thr kinase Stk in vitro. Mass spectrometric analyses identify Thr32, Thr36 and Ser415 as phosphoacceptors. The cognate phosphatase Stp dephosphorylates these phosphorylation sites. Moreover, Stk interacts with FemA and FemB, but is unable to phosphorylate them. Our data indicate that Stk and Stp modulate cell wall synthesis and cell division at several levels.},
  language  = {en}
}
@article{MarcuBichmannKuchenbeckeretal.2021,
  author    = {Marcu, Ana and Bichmann, Leon and Kuchenbecker, Leon and Kowalewski, Daniel Johannes and Freudenmann, Lena Katharina and Backert, Linus and M{\"u}hlenbruch, Lena and Szolek, Andr{\´a}s and L{\"u}bke, Maren and Wagner, Philipp and Engler, Tobias and Matovina, Sabine and Wang, Jian and Hauri-Hohl, Mathias and Martin, Roland and Kapolou, Konstantina and Walz, Juliane Sarah and Velz, Julia and Moch, Holger and Regli, Luca and Silginer, Manuela and Weller, Michael and L{\"o}ffler, Markus W. and Erhard, Florian and Schlosser, Andreas and Kohlbacher, Oliver and Stevanović, Stefan and Rammensee, Hans-Georg and Neidert, Marian Christoph},
  title     = {HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy},
  series = {Journal for ImmunoTherapy of Cancer},
  volume    = {9},
  journal   = {Journal for ImmunoTherapy of Cancer},
  doi       = {10.1136/jitc-2020-002071},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-370160},
  year      = {2021},
  abstract  = {Background The human leucocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Understanding the benign HLA ligand repertoire is a prerequisite to define safe T-cell-based immunotherapies against cancer. Due to the poor availability of benign tissues, if available, normal tissue adjacent to the tumor has been used as a benign surrogate when defining tumor-associated antigens. However, this comparison has proven to be insufficient and even resulted in lethal outcomes. In order to match the tumor immunopeptidome with an equivalent counterpart, we created the HLA Ligand Atlas, the first extensive collection of paired HLA-I and HLA-II immunopeptidomes from 227 benign human tissue samples. This dataset facilitates a balanced comparison between tumor and benign tissues on HLA ligand level. Methods Human tissue samples were obtained from 16 subjects at autopsy, five thymus samples and two ovary samples originating from living donors. HLA ligands were isolated via immunoaffinity purification and analyzed in over 1200 liquid chromatography mass spectrometry runs. Experimentally and computationally reproducible protocols were employed for data acquisition and processing. Results The initial release covers 51 HLA-I and 86 HLA-II allotypes presenting 90,428 HLA-I- and 142,625 HLA-II ligands. The HLA allotypes are representative for the world population. We observe that immunopeptidomes differ considerably between tissues and individuals on source protein and HLA-ligand level. Moreover, we discover 1407 HLA-I ligands from non-canonical genomic regions. Such peptides were previously described in tumors, peripheral blood mononuclear cells (PBMCs), healthy lung tissues and cell lines. In a case study in glioblastoma, we show that potential on-target off-tumor adverse events in immunotherapy can be avoided by comparing tumor immunopeptidomes to the provided multi-tissue reference. Conclusion Given that T-cell-based immunotherapies, such as CAR-T cells, affinity-enhanced T cell transfer, cancer vaccines and immune checkpoint inhibition, have significant side effects, the HLA Ligand Atlas is the first step toward defining tumor-associated targets with an improved safety profile. The resource provides insights into basic and applied immune-associated questions in the context of cancer immunotherapy, infection, transplantation, allergy and autoimmunity. It is publicly available and can be browsed in an easy-to-use web interface at https://hla-ligand-atlas.org .},
  language  = {en}
}